Similar long ‐term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV‐1‐infected patients in a retrospective, real‐life cohort of 14 years

HIV Medicine, EarlyView.

Source: HIV Medicine - July 4, 2018 Category: Infectious Diseases Authors: I Krznaric , M Bickel , A Carganico , P De Leuw , A Haberl , G Knecht , C Koegl , P Lauscher , G Sch üttfort , C Stephan , E Wolf , T Wolf Source Type: research